WO2009021585A1 - Bactéries probiotiques pour réduire l'occurrence de symptômes d'infections hivernales - Google Patents

Bactéries probiotiques pour réduire l'occurrence de symptômes d'infections hivernales Download PDF

Info

Publication number
WO2009021585A1
WO2009021585A1 PCT/EP2008/005661 EP2008005661W WO2009021585A1 WO 2009021585 A1 WO2009021585 A1 WO 2009021585A1 EP 2008005661 W EP2008005661 W EP 2008005661W WO 2009021585 A1 WO2009021585 A1 WO 2009021585A1
Authority
WO
WIPO (PCT)
Prior art keywords
probiotic bacteria
symptoms
lactobacillus
infections
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/005661
Other languages
English (en)
Inventor
Angelika Herzog
Antonius Johannes Maria Happel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of WO2009021585A1 publication Critical patent/WO2009021585A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to the use of probiotic bacteria (probiotics), especially probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof to reduce the impact of winter infections in healthy adults.
  • probiotic bacteria especially probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof to reduce the impact of winter infections in healthy adults.
  • probiotic bacteria denotes a live or attenuated bacterium, which provides specific health benefits to the host when consumed as a food component or supplement and beneficially affects the host cell by improving its microbial balance.
  • Probiotics including Lactobacillus and Bifidobacillus have a Ion g history of safe use in the dairy industry (Shortt C. Trends in Food Science and Technology 10: 411 (1999)). Fermented milk products and especially yoghurt represent the main source of probiotics in human diet. The consumer awareness of probiotics is the highest in Japan with Europe coming in second and the United States a distant third (Scheinbach S. Biotechnol Adv 16: 581 (1998)). In Japan full- scale bifidus and yogurt production has a long history of safe use; beginning in 1977 with home delivery of products containing Bifidobacterium longum and S. thermophilus. By 1984 the number of fermented products in Japan had reached 20 (lchikawa. Functional Foods, Designer Foods (1993)).
  • lactobacilli and bifido bacteria are extremely rare (Saxelin M, et al. CHn Infect Dis 22: 564 (1996) ; Gasser F. Bulletin de L'lnstitut Pasteur 92: 45 (1994)) and estimated to represent 0.05 % to 0.4 % of cases of infective endocarditis and bacteraemia, however a recent study found no correlation between an increased incidence of bacteraemia and increased usage of probiotic lactobacilli (Salminen S, Arvilommi H. CHn Infect Dis 32: 1577 (2001)).
  • probiotic microorganisms are known to exert a positive effect on a broad range of functions related to stimulation of the host's immune system (Clancy R, Gleeson, M., Cox, A., Dorrington, M., D'Este, C 1 Callister, P., Pyne, D., Fricker, P., Pang, G., Henriksson, A. In preparation (2005)).
  • bifidobacteria and lactobacilli are thought to have most beneficial effects on the human host (Orrhage K, Nord CE. Drugs Exp CHn Res 26: 95 (2000)).
  • probiotic bacteria especially probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof can be used to reduce the impact of winter infections in healthy adults.
  • object of the present invention is the use of probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof for preparing a composition which can be administered orally to reduce
  • wound infections especially denotes common cold, influenzal infection and/or flu, especially to common cold, influenzal infection and/or flu occurring from November to March in the northern hemisphere and from May to September in the southern hemisphere.
  • systemic symptoms of winter infections denotes symptoms such as headache, muscle ache, fatigue and/or temperature and is used in contrast to typical local symptoms such as sore or scratchy throat, hoarseness, nasal congestion, runny nose, cough, sneezing and/or ear ache.
  • severe symptoms of winter infections denotes symptoms that disturb and irritate the human during a winter infection most of the time and are ranked with a "3" in a ranking system ranging from 0 to 3, whereas
  • migraine denotes analgesics (painkillers to relieve (minor) aches and pains), antipyretics (drugs to reduce fever), and/or anti-inflammatory drugs.
  • the probiotic bacteria are preferably selected from one or both of the following groups:
  • Lactobacillus acidophilus Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus helveticus, Lactobacillus fermentum and mixtures thereof
  • Bifidobacteriae Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis and mixture thereof.
  • Lactobacillus acidophilus is especially preferred. - A -
  • the probiotic bacteria are selected from the group consisting of
  • Lactobacillus acidophilus CBS 116411 (LAFTI ® L10), Lactobacillus casei CBS 116412 (LAFTI ® L26) - both deposited at the Centraal Bureau voor Schimmel Cultures at 15 October 2004 - and Bifidobacterium lactis B94 CBS 118529 (LAFTI ® B94), deposited at the Centraal Bureau voor Schimmel Cultures at 14 September 2005.
  • the mentioned LAFTI ® products are obtainable at DSM Food Specialties.
  • LAFTI ® B94 and LAFTI ® L26 originate from human intestinal origin, whereas LAFTI ® L10 is of dairy origin. The use of LAFTI ® L10 is especially preferred.
  • the probiotic comprises a biologically pure culture of said deposited strain.
  • the probiotic comprises a biologically pure culture of said deposited strain in combination with any other valuable probiotic strain.
  • the composition according to the present invention may be a food composition or a dietary supplement, e.g. in form of a tablet, granule, capsule, paste, food additive, feed additive.
  • a food composition are chocolate (bars), cereals and cereal bars containing said chocolate and fermented dairy products (e. g. buttermilk, soured milk, yogurt (drinks), curd, quark desserts and so on) containing said probiotic bacteria.
  • the human is preferably a healthy adult, i.e. a human that is more than 16 years old and does not suffer from any known immune deficiency.
  • the composition comprises a probiotic in combination with a prebiotic.
  • prebiotic denotes a component, which has a favorable influence on the growth of probiotics.
  • prebiotic is selected from the group consisting of pentosans (or arabinoxylans), b-glucans, pectins, and pectic polysaccharides, mannans, Case 26287
  • fructo-oligosaccharides are selected from the group consisting of inulin, banana fiber, and soy fructo-oligosaccharides or soy oligosaccharides.
  • Most preferred mannans are selected from the group consisting of guar gum, locust bean gum, konjac and ad xanthan gum.
  • Resistant starch as used in the context of this invention includes those forms defined as RS1 , RS2, RS3, and RS4 in Brown et al (Brown, Mc Knaught and Moloney (1995) Food Australia 47:272-275). Resistant starch and modified resistant starch have been both extensively described in US 6,348,452.
  • the susceptibility to respiratory infections declines with age - the age range of the screened subjects was restricted to 18 to 25 years. Furthermore only students were recruited to avoid socioeconomic factors such as the density, housing, and distribution of the study population as well as family structure and exposure to children.
  • LAFTI ® L10 was taken at a daily dose of 5 x 10 9 CFU in one application. It was normally taken in the morning with breakfast (one capsule with 5 x 10 9 CFU LAFTI ® L10).This treatment was administered for 10 consecutive weeks.
  • Control 663 days with a score 3
  • the total occurrence with symptoms rated as 1 or 2 differs not significantly between the two groups (p >0.05).
  • Control 2762 days without a symptom

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur l'utilisation de bactéries probiotiques choisies dans le groupe constitué par des espèces Lactobacillus, Bifidobacterium et des mélanges de celles-ci pour préparer une composition qui peut être administrée par voie orale pour réduire l'occurrence de symptômes systémiques d'infections hivernales ; l'occurrence de symptômes d'infections hivernales graves ; l'utilisation d'une médication pendant les infections hivernales chez les humains.
PCT/EP2008/005661 2007-08-13 2008-07-11 Bactéries probiotiques pour réduire l'occurrence de symptômes d'infections hivernales Ceased WO2009021585A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93544007P 2007-08-13 2007-08-13
US60/935,440 2007-08-13

Publications (1)

Publication Number Publication Date
WO2009021585A1 true WO2009021585A1 (fr) 2009-02-19

Family

ID=39737153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/005661 Ceased WO2009021585A1 (fr) 2007-08-13 2008-07-11 Bactéries probiotiques pour réduire l'occurrence de symptômes d'infections hivernales

Country Status (1)

Country Link
WO (1) WO2009021585A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078322A2 (fr) * 1999-06-21 2000-12-28 Vsl Pharma Limited Combinaison de bacteries d'acide lactique et son utilisation pour prevenir et/ou traiter les infections et les etats inflammatoires
WO2001089541A1 (fr) * 2000-05-25 2001-11-29 Compagnie Gervais Danone Utilisation de lactobacillus casei dans des peptides immunostimulantes
WO2006007526A1 (fr) * 2004-07-01 2006-01-19 Bristol Myers Squibb Company Methode de prevention ou de traitement des infections respiratoires et de l'otite moyenne aigue chez l'enfant
WO2006048446A1 (fr) * 2004-11-05 2006-05-11 Dsm Ip Assets B.V. Lactobacillus pour prevenir et/ou traiter le syndrome de fatigue chronique et des maladies associees
WO2006048457A1 (fr) * 2004-11-05 2006-05-11 Dsm Ip Assets B.V. Probiotiques et polyphenol
WO2006054135A1 (fr) * 2004-11-16 2006-05-26 Anidral S.R.L. Composition a base de bacteries probiotiques et son utilisation en vue de prevenir et/ou de traiter des pathologies et/ou des infections respiratoires et d’ameliorer la fonctionnalite intestinale

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078322A2 (fr) * 1999-06-21 2000-12-28 Vsl Pharma Limited Combinaison de bacteries d'acide lactique et son utilisation pour prevenir et/ou traiter les infections et les etats inflammatoires
WO2001089541A1 (fr) * 2000-05-25 2001-11-29 Compagnie Gervais Danone Utilisation de lactobacillus casei dans des peptides immunostimulantes
WO2006007526A1 (fr) * 2004-07-01 2006-01-19 Bristol Myers Squibb Company Methode de prevention ou de traitement des infections respiratoires et de l'otite moyenne aigue chez l'enfant
WO2006048446A1 (fr) * 2004-11-05 2006-05-11 Dsm Ip Assets B.V. Lactobacillus pour prevenir et/ou traiter le syndrome de fatigue chronique et des maladies associees
WO2006048457A1 (fr) * 2004-11-05 2006-05-11 Dsm Ip Assets B.V. Probiotiques et polyphenol
WO2006054135A1 (fr) * 2004-11-16 2006-05-26 Anidral S.R.L. Composition a base de bacteries probiotiques et son utilisation en vue de prevenir et/ou de traiter des pathologies et/ou des infections respiratoires et d’ameliorer la fonctionnalite intestinale

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DE VRESE M ET AL: "Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: A double blind, randomized, controlled trial", CLINICAL NUTRITION, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 24, no. 4, 1 August 2005 (2005-08-01), pages 481 - 491, XP004996029, ISSN: 0261-5614 *
HATAKKA K ET AL: "Effect of long term consumption of probiotic milk on infections in children attending day care centres: Double blind, randomised trial", BMJ. BRITISH MEDICAL JOURNAL, LONDON, GB, vol. 322, no. 7298, 2 June 2001 (2001-06-02), pages 1327 - 1329, XP009055425, ISSN: 0959-8146 *
TURCHET P ET AL: "Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study.", THE JOURNAL OF NUTRITION, HEALTH & AGING 2003, vol. 7, no. 2, 2003, pages 75 - 77, XP009105928, ISSN: 1279-7707 *

Similar Documents

Publication Publication Date Title
Thomas et al. Probiotics and prebiotics in pediatrics
Rauch et al. The potential for probiotic manipulation of the gastrointestinal microbiome
Gill et al. Probiotics and human health: a clinical perspective
Senok et al. Probiotics: facts and myths
Zago et al. Characterization and probiotic potential of Lactobacillus plantarum strains isolated from cheeses
Sharma et al. RETRACTED: Probiotics: A Comprehensive Approach toward Health Foods
Mattila-Sandholm et al. Probiotics: towards demonstrating efficacy
CN102548566B (zh) 植物乳杆菌菌株用作降血胆固醇试剂
Ismail et al. Probiotic effects in allergic disease
CN101744841B (zh) 用于治疗炎性疾病的双歧杆菌
Bhadoria et al. Prospects, technological aspects and limitations of probiotics-a worldwide review.
JP6796070B2 (ja) 難消化性成分を含む飲食品および大腸内水素ガス産生剤
US20110165127A1 (en) Dairy-derived probiotic compositions and uses thereof
MX2008011450A (es) Mezcla simbiotica.
JP2013517784A (ja) 腸炎症の処置における使用のためのプロバイオティクス組成物
Kolida et al. Gastrointestinal microflora: probiotics
Yakoob et al. Bifidobacterium sp as Probiotic Agent-Roles and Applications.
CN101076346B (zh) 乳酸菌及其在预防腹泻中的应用
Young et al. Probiotic use in irritable bowel syndrome
Arora et al. Therapeutic potential of probiotics: A ray of hope or nightmare?
Tijjani et al. Probiotics and their attributes in human health therapy
Sarsan et al. Probiotics and Prebiotics: Health Benefits and Applications in Dietary Supplements
Irokanulo et al. Probiotics for Gastrointestinal Health and General Wellbeing.
Dastoor et al. Probiotics for life–Part I general health perspectives
Schellack et al. Overview of prebiotics, probiotics and synbiotics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08784702

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08784702

Country of ref document: EP

Kind code of ref document: A1